J&J says new prostate cancer pill shrinks tumours in early trial
Johnson & Johnson said its experimental once-daily pill JNJ-6143 shrank or eliminated tumours in patients with advanced prostate cancer who had received multiple treatments. The company presented the early-stage data at the European Society for Medical Oncology Congress.
At the 50mg dose, PSA levels fell by at least 50% in 77% of 31 evaluable patients. PSA levels fell by at least 90% in 48% of patients. Among patients with measurable tumours, 69% had a confirmed complete or partial response.
One patient stopped treatment because of adverse effects. Johnson & Johnson said the drug kills cancer cells selectively by interfering with a protein they need to survive.
A company spokesperson said: "It adds a new mechanism of action to J&J’s prostate cancer portfolio". Johnson & Johnson gained access to the drug through its deal to buy Halda Therapeutics for $3.05bn (R50.6bn) last year.
Key facts
- Who
- Johnson & Johnson (pharmaceutical company developing JNJ-6143); Halda Therapeutics (company J&J agreed to buy for $3.05bn last year)
- What
- Johnson & Johnson reported early-stage trial data for JNJ-6143, an experimental oral prostate cancer drug, in patients with advanced prostate cancer who had received multiple treatments. The data were presented at the European Society for Medical Oncology Congress.
- When
- 24 October 2026
- Where
- European Society for Medical Oncology Congress
- Status
- Reported